Expand ALLO Menu
ALLO MENU

ALLO Stock Posts


Upcoming Earnings

ALLO Allogene Therapeutics3.30+0.08 (+2.5%)

Allogene Therapeutics will report earnings after the market closes. View Calendar The market is expecting a ±9.6% move after earnings are reported. The average move for the past 4 quarters of earnings has been ±7.1%. View Expected Move (Conf Call: Nov 7 5:00 PM)
Upcoming Earnings

ALLO Allogene Therapeutics2.64+0.09 (+3.5%)

Allogene Therapeutics will report earnings after the market closes. View Calendar The market is expecting a ±10.7% move after earnings are reported. The average move for the past 4 quarters of earnings has been ±8.4%. View Expected Move (Conf Call: Aug 7 5:00 PM)
Upcoming Earnings

ALLO Allogene Therapeutics2.83+0.07 (+2.5%)

Allogene Therapeutics will report earnings after the market closes. View Calendar The market is expecting a ±11.0% move after earnings are reported. The average move for the past 4 quarters of earnings has been ±11.1%. View Expected Move (Conf Call: May 13 5:00 PM)
Upcoming Earnings

ALLO Allogene Therapeutics4.63-0.25 (-5.1%)

Allogene Therapeutics will report earnings after the market closes. View Calendar The market is expecting a ±8.7% move after earnings are reported. The average move for the past 4 quarters of earnings has been ±10.2%. View Expected Move (Conf Call: Mar 14 5:00 PM)
ALLO #AllogeneTherapeutics stock declines -18.9% in premarket,

Premarket Decliner

ALLO Allogene Therapeutics3.39+0.06+1.8%

Premarket:2.75-0.64 (-18.9%)

Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma

Globe NewswireThu, 4-Jan 4:15 PM
Unusual Option Volume

ALLO Allogene Therapeutics3.66+0.45 (+14.0%)

Allogene Therapeutics trades 2,176 contracts. The highest volume is in the 16-Feb-24 5 calls, which is 36.6% above the current price.
View Details...
Load Earlier Posts